23052-81-5
23052-81-5 結(jié)構(gòu)式
物理化學性質(zhì)
安全數(shù)據(jù)
知名試劑公司產(chǎn)品信息
| 報價日期 | 產(chǎn)品編號 | 產(chǎn)品名稱 | CAS號 | 包裝 | 價格 |
| 2025/12/22 | HY-100781A | L(+)-2-氨基-4-膦酰基丁酸 L-AP4 | 23052-81-5 | 1 mg | 1300元 |
| 2025/12/22 | HY-100781A | L(+)-2-氨基-4-膦?；∷?BR>L-AP4 | 23052-81-5 | 5mg | 3250元 |
| 2025/12/22 | HY-100781A | L(+)-2-氨基-4-膦?；∷?BR>L-AP4 | 23052-81-5 | 10 mM * 1 mLin Water | 3575元 |
常見問題列表
|
mGlu 4 0.13 μM (EC 50 ) |
mGlu8 0.29 μM (EC 50 ) |
mGlu 6 1.0 μM (EC 50 ) |
mGlu7 249 μM (EC 50 ) |
Paw withdrawal threshold in response to application of von Frey filaments before spinal nerve ligation is 22.6±2.4 g. The mechanical threshold decreases significantly (2.3±0.5 g, P<0.05) within 10 days after nerve ligation and remains stable for at least 8 weeks. Intrathecal injection of 5 to 30 μg of L-APB significantly increases the paw withdrawal threshold in response to application of von Frey filaments in eight nerve-ligated rats in a dose-dependent manner. The maximal effect of L-APB appears within 45 min and gradually subsided in 120 min following intrathecal administration.